1. Home
  2. NCNA vs BGLC Comparison

NCNA vs BGLC Comparison

Compare NCNA & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NuCana plc

NCNA

NuCana plc

N/A

Current Price

$1.09

Market Cap

4.0M

Sector

Health Care

ML Signal

N/A

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$1.13

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCNA
BGLC
Founded
1997
2017
Country
United Kingdom
Malaysia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
3.8M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
NCNA
BGLC
Price
$1.09
$1.13
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 75.0K
6.2K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 45.78
EPS
★ N/A
N/A
Revenue
N/A
★ $7,424,911.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.95
$1.05
52 Week High
$4.55
$5.65

Technical Indicators

Market Signals
Indicator
NCNA
BGLC
Relative Strength Index (RSI) 43.62 29.98
Support Level $0.95 N/A
Resistance Level $1.40 $1.39
Average True Range (ATR) 0.06 0.05
MACD 0.02 -0.01
Stochastic Oscillator 47.73 10.26

Price Performance

Historical Comparison
NCNA
BGLC

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.

Share on Social Networks: